← Oncology Approval Tracker

FDA DECISION ·

Pemetrexed Injection (Actavis) + cisplatin

pemetrexed plus cisplatin · Actavis

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Initial therapy with cisplatin for locally advanced or metastatic nonsquamous NSCLC, using the specified pemetrexed product.

LAMPGEN ANALYSIS

Why it matters

The supplement adds a cisplatin-based first-line indication separate from the same-day immunochemotherapy indication.

What research teams should watch

Check nonsquamous histology and distinguish this doublet from the pembrolizumab-based regimen.

PRIMARY RECORDS

Sources